← Eichor
Study identifier: NCT06437977 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)

Condition: Stage II-III Non-small Cell Lung Cancer  ·  Sponsor: Shanghai Chest Hospital

PhasePhase 3
Planned participants478
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable, stage II-III NSCLC.

This description comes directly from the study's public registry record.

Talk to the study team

Xuwei Cai  ·  02122200000  ·  birdhome2000@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Chest HospitalShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06437977